ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for Rolontis (eflapegrastim)
August 10, 2021Spectrum Pharmaceuticals today announced receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company’s Biologics License Application (BLA) for Rolontis® (eflapegrastim). -
Spectrum Submits BLA for ROLONTIS
December 29, 2018Spectrum Pharmaceuticals announced the company submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ROLONTIS (eflapegrastim).
Pharma Sources Insight January 2025
